Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Serina Therapeutics (SER) Interest Expenses (2021 - 2025)

Serina Therapeutics (SER) has disclosed Interest Expenses for 5 consecutive years, with $198000.0 as the latest value for Q4 2025.

  • Quarterly Interest Expenses rose 1064.71% to $198000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $213000.0 through Dec 2025, down 59.51% year-over-year, with the annual reading at $213000.0 for FY2025, 59.51% down from the prior year.
  • Interest Expenses hit $198000.0 in Q4 2025 for Serina Therapeutics, up from $6000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $978000.0 in Q4 2022 to a low of $6000.0 in Q3 2025.
  • Historically, Interest Expenses has averaged $301411.8 across 5 years, with a median of $186000.0 in 2024.
  • Biggest YoY gain for Interest Expenses was 1064.71% in 2025; the steepest drop was 97.07% in 2025.
  • Year by year, Interest Expenses stood at $295000.0 in 2021, then soared by 231.53% to $978000.0 in 2022, then crashed by 82.0% to $176000.0 in 2023, then crashed by 90.34% to $17000.0 in 2024, then surged by 1064.71% to $198000.0 in 2025.
  • Business Quant data shows Interest Expenses for SER at $198000.0 in Q4 2025, $6000.0 in Q3 2025, and $9000.0 in Q2 2025.